Amivantamab In Patients With Egfr Ex20Ins-Mutated Nsclc

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutations

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

Amivantamab for NSCLC with MET Exon 14 skipping mutations

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

European Society for Medical Oncology (ESMO)

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video Library

GRACE - Global Resource for Advancing Cancer Education

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLC

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20

GRACE - Global Resource for Advancing Cancer Education

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

European Society for Medical Oncology (ESMO)

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC